Kiniksa Pharmaceuticals reported first quarter 2025 ARCALYST net product revenue of $137.8 million. This figure represents a 75% increase compared to the same period in 2024, driven by an expanded prescriber base, longer average treatment duration, and changes to the Medicare Part D program.
Based on this strong performance, the company increased its full-year 2025 ARCALYST net sales guidance to a range of $590 million to $605 million. This is an increase from the previous guidance of $560 million to $580 million, reflecting confidence in continued market momentum.
The KPL-387 Phase 2/3 clinical trial in recurrent pericarditis remains on track to initiate in mid-2025, with Phase 2 data still expected in the second half of 2026. Kiniksa reiterated its expectation to remain cash flow positive on an annual basis under its current operating plan.
Management highlighted the potential of KPL-387 to offer an additional treatment option for patients, with a target of monthly subcutaneous injection in a liquid formulation. This pipeline asset aims to further solidify Kiniksa's leadership in the recurrent pericarditis market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.